Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Madrigal Pharmaceuticals (MDGL) Return on Sales (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Return on Sales for 9 consecutive years, with 0.18% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Sales rose 39.0% to 0.18% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.3%, a 229.0% increase, with the full-year FY2025 number at 0.3%, up 229.0% from a year prior.
  • Return on Sales was 0.18% for Q4 2025 at Madrigal Pharmaceuticals, up from 0.39% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.18% in Q4 2025 to a low of 281.36% in Q2 2021.
  • A 3-year average of 62.39% and a median of 0.58% in 2024 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: tumbled -24776bps in 2021, then skyrocketed 1018bps in 2025.
  • Madrigal Pharmaceuticals' Return on Sales stood at 281.36% in 2021, then skyrocketed by 100bps to 0.58% in 2024, then skyrocketed by 68bps to 0.18% in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Return on Sales are 0.18% (Q4 2025), 0.39% (Q3 2025), and 0.2% (Q2 2025).